{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Complete Remission (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Stringent Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Very good partial remission (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Partial Remission (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Overall response defined as number of participants with International Myeloma Working Group Uniform Response Criteria: Complete Response (CR): Negative immunofixation serum \\& urine, Disappearance soft tissue plasmacytomas \\& =/\\<5% plasma cells in bone marrow; Stringent Complete Remission: CR + Normal Normal free light chain (FLC) ratio \\& Absence clonal cells in bone marrow by Immunohistochemistry/ immunofluorescence; Very Good Partial Response (VGPR): Serum \\& urine M-protein detectable by immunofixation but not on electrophoresis or 90%\\> reduction in serum M-protein +urine M-protein level \\<100mg per 24 hour; Partial Remission (PR): =/\\>50% reduction serum M-protein \\& reduction in 24-hour urinaryMprotein by \\>90% or to \\< 200mg per 24 hour, =/\\>50% reduction of serum M-protein \\& reduction in 24-hour urinary Mprotein by \\>90%/or \\<200mg, and if present at baseline, a \\>50% reduction in size of soft tissue plasmacytomas; Stable Disease: Not CR, VGPR, PR Or Progressive disease","groups":[{"description":"Induction of Lenalidomide 25 mg orally Days 1-14; Bortezomib 1.3 mg/m\\^2 intravenous Days 1, 4, 8 and 11; Dexamethasone 20 mg orally Days 1, 2, 4, 5, 8, 9, 11, 12. Siltuximab 11 mg/kg intravenous Day 1. If delayed transplant, induction therapy continued up to 2 cycles beyond achieving a CR/nCR then transition to maintenance therapy (Lenalidomide at last tolerated dose Day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg). Siltuximab 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy. Bortezomib at last tolerated dose Day 1 and Day 8 Dexamethasone at last tolerated dose or 20 mg weekly.","id":"OG000","title":"Siltuximab + Bortezomib + Lenalidomide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Evaluated after eight cycles of 21 days.","title":"Number of Participants With Response","type":"SECONDARY","unitOfMeasure":"participants"}